EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exosomal miR‐3126‐5p derived from cancer‐associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis

Zhenyu Zhang, Haicheng Ma, Yingying Zheng, Lina Wang, Chenghui Wang, Yuanyuan Liu, Hengxiao Lu, Shaoqiang Wang

Clinical and Translational Medicine · 2025-12 · 15 (12)

DOI: 10.1002/ctm2.70554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 18.12.2025. Verfasst von Zhenyu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, MicroRNAs, Cancer-Associated Fibroblasts, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shangdong Provincial Natural Science Founding, Shandong Medical Association Young Talent Nurturing Project, Kite Capital Distinguished Expert Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As a critical component of the tumour microenvironment, cancer‐associated fibroblasts (CAFs) actively drive the malignant advancement of non‐small‐cell lung cancer (NSCLC); however, their underlying mechanisms continue to be poorly characterized. This work examined the role of CAFs‐derived exosomal miR‐3126‐5p in the glycolysis of NSCLC cells.

Methods

Glycolysis was evaluated by lactate production, glucose uptake, oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). Cell proliferation and cycle were evaluated by CCK‐8, EdU staining, and flow cytometry. Src homology 2B adaptor protein 1 (SH2B1) and insulin receptor substrate 1 (IRS1) protein interaction was tested by Co‐IP and GST pull‐down assay. ChIP, dual‐luciferase reporter assay, and EMSA determined the binding of kruppel‐like factor 13 (KLF13) to the SH2B1 promoter. Dual‐luciferase reporter assay was applied to assess miR‐3126‐5p binding to KLF13 3′‐UTR. In vivo growth of NSCLC was determined in the mouse xenograft and Lewis lung carcinoma models.

Results

CAFs‐derived exosomal miR‐3126‐5p was highly expressed in NSCLC tissues, and its elevated plasma level was significantly associated with poor prognosis of NSCLC patients. CAFs‐derived exosomal miR‐3126‐5p facilitated glycolysis to accelerate the malignant progression of NSCLC cells. KLF13 exhibited reduced expression in NSCLC, while its overexpression suppressed NSCLC growth via repressing glycolysis. Exosomal miR‐3126‐5p targeted KLF13 3′‐UTR to inhibit its expression in NSCLC cells. KLF13 transcriptionally inhibited SH2B1 expression to abolish the interaction between SH2B1 and IRS1 proteins, thus repressing PI3K/AKT pathway‐mediated glycolysis. KLF13 knockdown counteracted the anti‐cancer action of exosomal miR‐3126‐5p inhibition.

Conclusion

CAFs‐derived exosomal miR‐3126‐5p accelerated NSCLC progression via inhibiting KLF13 expression, which transcriptionally activated SH2B1 to promote its interaction with IRS1, thereby promoting PI3K/AKT pathway‐mediated glycolysis. Our findings position CAFs‐secreted exosomal miR‐3126‐5p as a novel therapeutic intervention with potential in NSCLC management. Highlights CAFs‐derived exosomal miR‐3126‐5p enhanced glycolysis of NSCLC cells via targeting KLF13. KLF13 led to transcriptional inhibition of SH2B1 in NSCLC cells. SH2B1 interplayed with IRS1 to facilitate glycolysis of NSCLC cells. IRS1 promoted glycolysis of NSCLC cells via the activation of PI3K/AKT pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungMicroRNAsCancer-Associated FibroblastsLung NeoplasmsKruppel-Like Transcription FactorsInsulin Receptor Substrate ProteinsHumansGlycolysisMiceAnimalsExosomesDisease ProgressionMaleCell Line, TumorFemale

Stichwörter der Autor:innen

KLF13SH2B1cancer‐associated fibroblastsexosomal miR‐3126‐5pglycolysisnon‐small‐cell lung cancer

Substanzen

MicroRNAsKruppel-Like Transcription FactorsInsulin Receptor Substrate ProteinsIRS1 protein, human

Autor:innen und Institutionen

  • Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, P.R. China.
  • Health Management Center, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, P.R. China.
  • Medical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, P. R. China.
  • Department of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, P. R. China.
  • Clinical laboratory, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, P. R. China.
  • Department of Thoracic Surgery, Weifang People's Hospital, Weifang Medical University, Weifang, Shandong, P. R. China.

Förderung

  • Shangdong Provincial Natural Science Founding
  • Shandong Medical Association Young Talent Nurturing Project
  • Kite Capital Distinguished Expert Fund

Zitieren

APA

Zhang, Z., Ma, H., Zheng, Y., Wang, L., Wang, C., Liu, Y., Lu, H., & Wang, S. (2025). Exosomal miR‐3126‐5p derived from cancer‐associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis. Clinical and Translational Medicine, 15(12). https://doi.org/10.1002/ctm2.70554

Vancouver

Zhang Z, Ma H, Zheng Y, Wang L, Wang C, Liu Y, et al. Exosomal miR‐3126‐5p derived from cancer‐associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis. Clinical and Translational Medicine. 2025;15(12). doi:10.1002/ctm2.70554

BibTeX
@article{Zhang2025,
  author = {Zhang, Zhenyu and Ma, Haicheng and Zheng, Yingying and Wang, Lina and Wang, Chenghui and Liu, Yuanyuan and Lu, Hengxiao and Wang, Shaoqiang},
  title = {Exosomal miR‐3126‐5p derived from cancer‐associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  volume = {15},
  number = {12},
  doi = {10.1002/ctm2.70554}
}
Kostenlos starten →